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David Altshuler2,3,4,*I first want to thank the nominators and the Society for this
wonderful award. It is an honor and more than a bit
humbling to be in the company of the previous winners.
I’d also like to thank Aravinda for his kind and generous
introduction. I have learned much from Aravinda over the
years, and it is a personal pleasure to share the podium
with him.
Given the time available, I won’t attempt to review the
science we’ve done over the last ten years. Rather, I would
like to briefly touch on three themes.
First is the unique role of human genetics as a tool for
biomedical research. Second is the critical importance of
statistical rigor and reproducibility. Third is the changing
nature of our field and how we rise to the grand challenge
of our collective success.
First is genetic mapping and causal inference.
I have come to the view that two aspects of human
genetics are particularly unique in the armamentarium of
biomedicine: the unbiased nature of genetic mapping
and the ability to draw causal inference in the human
population.
Mostof science ishypothesisdrivenand is thushypothesis
limited. Genetic mapping reveals new biological mecha-
nisms without regard to our preconceptions about whether1This article is based on the address given by the author at the meeting of the In
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The Amethey involve known or novel genes, alter protein coding
or noncoding regions, and are few in number or many.
Ed Lewis oncewrote, ‘‘The laws of genetics have never de-
pended upon knowing what the genes are chemically and
would hold true even if they were made of green cheese.’’
Similarly, it seems to me that the virtue of genetic
mapping is that it doesn’t depend on our guesses about
whether the variants should reside in the genes that biolo-
gists have previously studied or if they are to be found
hundreds of kilobases from the nearest recognized func-
tional element.
If unbiased search is the hallmark of our approach, then
it is incumbent on us to see with clear eyes what the data
are telling us even when the answers don’t support our
prior assumptions.
Of course, human geneticists are not unique in trying to
find novel causes for disease. However, our approach is
special because of its ability to support causal inference
in the human population. Here, I don’t mean ‘‘the’’ cause
(there is never just one cause), but rather the key difference
between a reactive process and one that participates in
a causal chain.
The two most commonly taken approaches in
biomedicine—experimental studies in the laboratory and
observational studies in human populations—are power-
ful, but each has fundamental limitations. Model systems
and cell cultures are highly tractable, but the findings are
of uncertain relevance to patients. Observational studies
in the human population can reveal correlations, but as
a matter of logic, they do not support causal inference.
Why is it that observational studies do not support causal
inference? At the core, the reasons are two: confounding
and the arrow of time. The exposures are not assigned at
random nor are they independent. For this reason, it is
always possible that a measured variable reflects the influ-
ence of some other unmeasured causal factor. Moreover,
expression levels, metabolites, and behaviors can and do
change in response to disease and thusmight follow, rather
than precede, the root cause of disease.
In contrast, geneticists can safely assume the random
assignment of gametes at meiosis and the independent
assortment of unlinked segments due to recombination.
(I’ll note that as a result of linkage and linkage dis-
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Moreover, the arrow of time is fixed at conception, and
genes don’t change in response to disease.
These two features are special to our approach. For these
reasons, I believe that the unique role of human genetics is
to expand the scope of knowledge of human biology and
to focus our attention on thosemechanisms that are causal
rather than reactive.
But there is a fly in the ointment. The genome is very big,
and each copy of the genome differs at millions of DNA
variants. Few of these variants influence any disease, and
those that do typically act in manner that is probabilistic,
not deterministic.
If our goal is to find a small number of needles in a very
large haystack—and it is—then our work demands a statis-
tical approach, carried out with great rigor and skeptically
interpreted under an appropriate null distribution. This
brings me to my second point.
Over the last ten years,many of us haveworked to enable
the systematic and comprehensive testing of genetic
variation for association to human diseases. This in-
volved characterizing and cataloguing human sequencing
variation, developing laboratory tools to measure that
variation, developing analytical methods to find associa-
tions to phenotype, and performing studies of sufficient
power to identify robust relationships between genetic
variations and disease.
As we know, the first generation of such studies has been
successful in identifying many novel genomic regions
associated with a wide variety of diseases. Now, based on
whole-genome and exome sequencing, a second genera-
tion of such studies is under way.
When I look back on the last five years, since genome-
wide association studies became a new tool in our arma-
mentarium, there is one element that strikes me as most
important to today.
That element is the high standards set for statistical rigor
in analysis and the demand that results be reproducible.
In the early days of linkage for complex traits and of
candidate-gene association studies, thereweremany claims
that proved to be impossible for replication. Oftentimes,
these were in candidate genes that someone thought
made sense and involved nonsynonymous changes that
someone thought might be functional. Many worried
that GWAS studies would drown in a sea of false claims.
History shows that the opposite has been the case. A set
of standards were developed and stringently applied,
ranging from proper controls for technical artifacts and
population mismatching to interpretation under a null
hypothesis that considers the entire genome to a require-
ment for replication prior to making claims. In return,
the vast majority of GWAS findings that meet these
standards have proven robust and reproducible.
I mention this because in the excitement around next-
generation sequencing, findings that lack sufficient statis-
tical evidence to justify the claim of a relationship to
phenotype are again being reported, and there is a disturb-
ing lack of concern for replication.408 The American Journal of Human Genetics 90, 407–409, March 9It almost appears as though some would argue that if
a variant is rare and alters a protein or creates a large struc-
tural variant, then the need for sober analysis, genome-
wide significance, and replication can be waived.
Karl Popper wrote, ‘‘The criterion of the scientific status
of a theory is its falsifiability or refutability or testability.’’
In the realm of next-generation sequencing, this means
that if the theory is that a given gene harbors mutations
that influence a disease, then that theory must be stated
in such a way that others can come along with an appropri-
ately sized sample and reproduce or refute the finding. If
others can’t replicate the finding, then the theory should
be revisedor set asideuntil it survives attempts at refutation.
Having said this, I have full confidence that as the
sample sizes increase and as convincing findings emerge,
the field will embrace high standards for statistical evi-
dence and replication of findings.
In fact, it now seems highly likely that when the history
books are written, they will say that from 1980 to 2020 or
so, geneticmapping revealed avastnumberof causal factors
for human diseases, first for rare single-gene disorders and
later for diseases showing complex inheritance. They will
describe that some diseases are caused by mutation at
only one or a few genes but that most diseases are influ-
enced by dozens to hundreds of genes. They will describe
both common and rare mutations, very few of which act
in a fully penetrant manner. Probability rather than deter-
minism will become the linchpin of our thinking.
This genetic anatomy of human diseases will be a grand
accomplishment shared by our entire field. It will lead to
an inventory of disease-associated genes that students
learn about in school, much like they do the bones of
the hand or the enzymes of the Krebs cycle.
But for this not to be a pyrrhic victory, we will need to
embrace the end of one way of thinking and focus on
a new grand challenge: figuring out the biological functions
of these many novel genes, their roles in pathophysiology,
and how to leverage this new information to develop new
andmoreeffective approaches topreventionandtreatment.
At present, much attention in our field focuses on the
proposition that clinical value will derive directly from
the sequencing and interpretation of genomes. In some
cases, it has and it will.
More generally, the value of prediction pales in com-
parison to the reward of more effective prevention and
treatment.
Of course, this is far from a new idea. The geneticists we
admire the most are, appropriately, those who have not
only found genes for a disease but who have also under-
stood them and developed new therapies. A previous recip-
ient of this award, Hal Dietz, described the path from the
discovery of genes for Marfan syndrome to an unexpected
pathophysiological mechanism to a novel treatment.
Hal is one of my heroes.
Nonetheless, it is sobering to recognize that in 2011, it
remains a very difficult task to figure out the function
of a new gene that is found convincingly to influence, 2012
a disease but that has no previously known biochemical or
cellular function. Confronted with not too few such genes
but too many, it is clear that we will need new frameworks
and approaches.
More importantly, doing this will require us to commit
the time and effort to doggedly pursuewhatwehave found.
Hal Dietz talks about a decade in the wilderness between
the cloning of the Marfan gene and the breakthroughs
that have led to therapies. Twenty years after the cloning
of the gene for Huntington disease, my friends Jim Gusella
and Marcy MacDonald and their many colleagues around
the world are still working to crack the problem.
This is not a sign of the failure of genetics, as the news-
papers sometime suggest, but simply what it takes to go
from a truly new finding to something useful.
When I was in graduate school, Fred Winston’s lab was
next door. Fred’s lab had performed genetic screens in yeast
and identified a number of novel genes that played a role
in transcription. Among these genes were components of
histones. At that time, the idea that histones played
a role in transcription was heretical.
I ate lunch every day with Joel Hirschhorn, a fellow
graduate student from that lab. Joel worked for years to
prove that this finding from genetics—that histones play
a role in transcription—was real and important. His work
was criticized by many leading lights in that field and
was dismissed as irrelevant.
But today, we all know that histones play a critical role in
transcription.
Similarly, Bruce Wightman, another friend in graduate
school, worked in Gary Ruvkun’s lab. Together with Victor
Ambros, he and Gary performed positional cloning of the
worm genes lin-4 and lin-14 and found a then inexplicable
result: One of these genes encoded a tiny noncoding RNA
complementary to the other. This observation didn’t fit
the dogma and was rejected by many as irrelevant or as
a boutique exception.
It was a decade before the general importance of their
finding of a microRNA was recognized.
I was lucky enough to encounter these inspiring exam-
ples early in my career. I took away from them that if a
geneticist believes what comes out of his or her screen
and studies it well and long enough, he or she can learn
important and novel things.
This highlights an unstated tension in our field:We extol
unbiased discovery as the sine qua non of human genetics,
and yet, we are understandably frustrated when we
uncover genes about which nothing is known. Too often,
we move on to the next gene discovery rather than study
what we’ve found. I’ve been guilty of that over the years,
but I’m not alone.
Another sobering fact is that many of us might not be
the right people, by training or inclination, to do this
next phase of work. That means either that we have to
retrain and dramatically shift gears or that we have to
recruit others to take up the challenge. One way or
another, it must be done, or the potential value of ourThe Amecollective accomplishment will be limited to fortune
telling and wishful thinking.
Which brings me to collaboration.
The nature of genetics and genomics has required that
many types of expertise be brought to bear on a single
problem, spanning from the clinical to the technological
to the statistical to the biological. Given the model of
a single PI working alone, it was difficult to see how such
a challenge could be met.
But necessity is the mother of invention. Faced with the
choice of working alone and failing, people chose to work
together. Instead of doing many underpowered studies,
they did one well-powered study. Instead of staying in
the comfort zone of their own subdiscipline, they sought
out people with complementary skills.
It has been remarkable to see teams define goals that, at
the time, seemed like they couldn’t be achieved, and then
accomplish them together. It’s been great fun to share these
years with a remarkable group of friends and colleagues.
Looking out for young people has been one of the key
aspects ofmaking collaborationwork. Although it is possible
for young people to get lost in a big project, such projects
offer a rich opportunity for those with ideas and initiative.
It is the jobof thementor toensure that each traineedevelops
his or her own ideas, writes papers and give talks, andmoves
purposefully toward his or her own personal goals.
As we shift from gene discovery to function and therapy,
the nature of the collaborations might change, but the
need for collaboration will increase, not decrease.
In closing, I’d like to thank those people who have been
my mentors, collaborators, and friends.
Eric Lander, who gave me my start in human genetics
and who taught me to believe that anything is possible.
Stacey Gabriel and Mark Daly, who have been partners
in establishing the Program in Medical and Population
Genetics at the Broad Institute and in too many studies
to name.
Joel Hirschhorn, whom I met the first day of medical
school and with whom I return each year to teach human
genetics to medical students.
Leif Groop, who 15 years ago welcomed me warmly as
his visitor in Malmo, Sweden. Since that day, we have
shared common cause in the goal of understanding the
genetics of type 2 diabetes.
More recently, Mike Boehnke and Mark McCarthy, with
whom we created the DIAGRAM Consortium and
a community that together is tackling diabetes genetics.
The members of our lab, who have brought their ideas,
energy, and good will to the work. Nothing in my pro-
fessional life has given me more pleasure than to watch
with awe as former trainees have gone on to make dis-
coveries, lead their own labs, or thrive in leadership roles
in research institutes and companies.
And finally, my parents, Julie and Alan Altshuler, my
wife, Jill, and my sons, Zachary and Jason. I love my
work, but my family is my life.
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